Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial...

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Primary percutaneous coronary intervention (PCI) is standard for ST-elevation myocardial infarction (STEMI).
• Cellular reperfusion injury, linked to calcium overload, can limit myocardial salvage.
• Previous CASTEMI trial data showed caldaret did not alter residual left ventricular (LV) function post-PCI.

Purpose of the Study:

• To evaluate if caldaret administration decreases the incidence of severe left ventricular dysfunction (LV ejection fraction ≤30%) in STEMI patients undergoing primary PCI.
• To analyze caldaret's effect on myocardial salvage and LV function recovery.

Main Methods:

• Subanalysis of 239 STEMI patients from the CASTEMI trial with SPECT data at days 7 and 30.
• Comparison of LV dysfunction incidence between low-dose caldaret, high-dose caldaret, and placebo groups.
• Assessment of LV ejection fraction at day 7 and day 30 post-infarction.

Main Results:

• A significant reduction in LV dysfunction incidence was observed at day 30 in both low-dose (8.0%) and high-dose (6.9%) caldaret groups compared to placebo (17.5%).
• The benefit was more pronounced in patients with anterior wall MI and Thrombolysis In Myocardial Infarction grade 0/1 flow, showing a 52% decrease in LV dysfunction by day 7.
• LV ejection fraction improvement was significant between days 7 and 30 in caldaret-treated patients, but not in the placebo group.

Conclusions:

• Intravenous caldaret treatment significantly decreases the incidence of severe left ventricular dysfunction in STEMI patients undergoing primary PCI.
• Caldaret demonstrates potential in mitigating reperfusion injury and improving cardiac function recovery after myocardial infarction.
• The findings support caldaret as a therapeutic option to enhance myocardial salvage and reduce long-term adverse LV remodeling in STEMI.